Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Dimebon reduces the levels of aggregated amyloidogenic protein forms in detergent-insoluble fractions in vivo.

Ustyugov AA, Shelkovnikova TA, Kokhan VS, Khritankova IV, Peters O, Buchman VL, Bachurin SO, Ninkina NN.

Bull Exp Biol Med. 2012 Apr;152(6):731-3. English, Russian.

PMID:
22803176
2.

[Study into molecular targets of a neuroprotective compound dimebon using a transgenic mice line].

Shelkovnikova TA, Ustiugov AA, Kokhan VS, Tarasova TV, Medvedeva VK, Khritankova IV, Bachurin SO, Ninkina NN.

Biomed Khim. 2014 May-Jun;60(3):354-63. Russian.

PMID:
25019398
3.

Dimebon slows progression of proteinopathy in γ-synuclein transgenic mice.

Bachurin SO, Shelkovnikova TA, Ustyugov AA, Peters O, Khritankova I, Afanasieva MA, Tarasova TV, Alentov II, Buchman VL, Ninkina NN.

Neurotox Res. 2012 Jul;22(1):33-42. doi: 10.1007/s12640-011-9299-y. Epub 2011 Dec 17.

4.

Ubiquitin proteasome system as a pharmacological target in neurodegeneration.

Hol EM, Fischer DF, Ovaa H, Scheper W.

Expert Rev Neurother. 2006 Sep;6(9):1337-47. Review.

PMID:
17009921
5.

Mice expressing the alpha(1B)-adrenergic receptor induces a synucleinopathy with excessive tyrosine nitration but decreased phosphorylation.

Papay R, Zuscik MJ, Ross SA, Yun J, McCune DF, Gonzalez-Cabrera P, Gaivin R, Drazba J, Perez DM.

J Neurochem. 2002 Nov;83(3):623-34.

6.

Modulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases: strategies and mechanisms.

Liu T, Bitan G.

ChemMedChem. 2012 Mar 5;7(3):359-74. doi: 10.1002/cmdc.201100585. Epub 2012 Feb 9. Review.

PMID:
22323134
7.

Beta-Synuclein-derived peptides with neuroprotective activity: an alternative treatment of neurodegenerative disorders?

Windisch M, Hutter-Paier B, Schreiner E, Wronski R.

J Mol Neurosci. 2004;24(1):155-65.

PMID:
15314265
8.

Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein.

Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM.

Neuron. 2002 May 16;34(4):521-33.

9.

Novel Sites of Neuroprotective Action of Dimebon (Latrepirdine).

Ustyugov A, Shevtsova E, Bachurin S.

Mol Neurobiol. 2015 Oct;52(2):970-8. doi: 10.1007/s12035-015-9249-4. Epub 2015 Jun 30. Review.

PMID:
26123670
10.

Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies.

Sampathu DM, Giasson BI, Pawlyk AC, Trojanowski JQ, Lee VM.

Am J Pathol. 2003 Jul;163(1):91-100.

11.

Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation.

Gispert S, Del Turco D, Garrett L, Chen A, Bernard DJ, Hamm-Clement J, Korf HW, Deller T, Braak H, Auburger G, Nussbaum RL.

Mol Cell Neurosci. 2003 Oct;24(2):419-29.

PMID:
14572463
12.

Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway.

Lee HJ, Khoshaghideh F, Patel S, Lee SJ.

J Neurosci. 2004 Feb 25;24(8):1888-96.

13.

Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders?

Windisch M, Wolf HJ, Hutter-Paier B, Wronski R.

Curr Alzheimer Res. 2007 Dec;4(5):556-61. Review.

PMID:
18220522
14.

Isoflurane preconditioning induces neuroprotection by attenuating ubiquitin-conjugated protein aggregation in a mouse model of transient global cerebral ischemia.

Zhang HP, Yuan LB, Zhao RN, Tong L, Ma R, Dong HL, Xiong L.

Anesth Analg. 2010 Aug;111(2):506-14. doi: 10.1213/ANE.0b013e3181e45519. Epub 2010 Jul 7.

PMID:
20610552
15.

[Proteinopathies--forms of neurodegenerative disorders with protein aggregation-based pathology].

Shelkovnikova TA, Kulikova AA, Tsvetkov FO, Peters O, Bachurin SO, Bukhman VL, Ninkina NN.

Mol Biol (Mosk). 2012 May-Jun;46(3):402-15. Review. Russian.

PMID:
22888630
16.
17.

Chronic administration of dimebon ameliorates pathology in TauP301S transgenic mice.

Peters OM, Connor-Robson N, Sokolov VB, Aksinenko AY, Kukharsky MS, Bachurin SO, Ninkina N, Buchman VL.

J Alzheimers Dis. 2013;33(4):1041-9. doi: 10.3233/JAD-2012-121732.

PMID:
23099813
18.

Catalpol ameliorates beta amyloid-induced degeneration of cholinergic neurons by elevating brain-derived neurotrophic factors.

Wang Z, Liu Q, Zhang R, Liu S, Xia Z, Hu Y.

Neuroscience. 2009 Nov 10;163(4):1363-72. doi: 10.1016/j.neuroscience.2009.07.041. Epub 2009 Jul 24.

PMID:
19635525
19.

Interactions of amyloidogenic proteins.

Giasson BI, Lee VM, Trojanowski JQ.

Neuromolecular Med. 2003;4(1-2):49-58. Review.

PMID:
14528052
20.

Interaction of myocilin with gamma-synuclein affects its secretion and aggregation.

Surgucheva I, Park BC, Yue BY, Tomarev S, Surguchov A.

Cell Mol Neurobiol. 2005 Sep;25(6):1009-33.

PMID:
16392033

Supplemental Content

Support Center